Acute Coronary Syndromes After TAVR: Frequent and Not All Undergo Coronary Angiography

Approximately 10% of patients who undergo transcatheter aortic valve replacement (TAVR) are readmitted for an acute coronary syndrome after a mean follow-up of 25 months. Male sex, prior coronary artery disease, and (surprisingly and hard to explain) nontransfemoral approach were independent predictors of acute coronary syndrome after TAVR, an event associated with high midterm mortality.

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVIWhile 50% of patients with aortic stenosis undergoing TAVR have concurrent coronary artery disease, the occurrence and clinical impact of coronary events after the aforementioned procedure remain largely unknown.

 

This study included all consecutive patients who underwent TAVR between 2007 and 2017. Patients were followed at 1, 6, and 12 months, and then yearly. Acute coronary syndromes were diagnosed and classified according to the Third Universal Definition of Myocardial Infarction (which is already obsolete, since the Fourth Definition was presented at the 2018 European Society of Cardiology [ESC] Congress in Munich).


Read also: Vascular Surgeons of the Future in the Endovascular Era.


A total of 779 patients (mean age 79 ± 9 years, 52% male, mean Society of Thoracic Surgeons [STS] mortality score: 6.8 ± 5.1%) were included, 68% of whom had a history of coronary artery disease. At a mean follow-up of 25 months (interquartile range: 10 to 44), 78 patients (10%) experienced at least one episode of acute coronary syndrome. One half of the events occurred within a year after implantation.

 

Clinical presentation was non-ST-segment elevation myocardial infarction (type 2, according to the Third Definition) in 35.9% of all cases, unstable angina in 34.6% of patients, non-ST-segment elevation myocardial infarction (type 1 according to the Third Definition) in 28.2% of cases, and ST-segment elevation myocardial infarction in 1.3% of patients.

 

Male sex doubled the chances of suffering a coronary event (hazard ratio [HR]: 2.19; 95% confidence interval [CI]: 1.36 to 3.54; p = 0.001), prior coronary artery disease almost tripled that risk (HR: 2.78; 95% CI: 1.50 to 5.18; p = 0.001), and nontransfemoral approach was also associated with higher risk (HR: 1.71; 95% CI: 1.04 to 2.75; p = 0.035).


Read also: In Diabetics with Multivessel Disease SYNTAX Score Calculations Are Redundant.


Almost 70% of patients underwent a coronary angiography during hospitalization and 56.6% underwent angioplasty. The in-hospital death rate at the time of the acute coronary syndrome episode was 3.8%. At a mean follow-up of 21 months after a hospitalization for acute coronary syndrome, all-cause and cardiovascular death rates were 37.3% and 25.3%, respectively.

 

Original title: Incidence, Clinical Characteristics, and Impact of Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement.

Reference: Victoria Vilalta et al. J Am Coll Cardiol Intv 2018;11:2523-33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....